EMYRIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.052 AUD | -1.89% |
|
+26.83% | 0.00% |
| Jul. 01 | Emyria Receives Grant to Develop MDMA Analog Drug Program; Shares Up 17% | MT |
| Jun. 20 | Emyria to Facilitate PTSD Treatment Trial | MT |
| Sales 2022 | 1.82 2.73 | Sales 2023 | 1.59 2.39 | Capitalization | 38.54M 57.75M |
|---|---|---|---|---|---|
| Net income 2022 | -7M -10.49M | Net income 2023 | -5M -7.49M | EV / Sales 2022 | 26,889,502 x |
| Net cash position 2022 | 3.25M 4.86M | Net cash position 2023 | 1.46M 2.19M | EV / Sales 2023 | 23,285,243 x |
| P/E ratio 2022 |
-6.91
x | P/E ratio 2023 |
-6.98
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.89% | ||
| 1 week | +26.83% | ||
| Current month | +26.83% | ||
| 1 month | -11.86% | ||
| 3 months | -14.75% | ||
| 6 months | -5.45% |
1 week
0.04
0.06
1 month
0.040.06
Current year
0.040.08
1 year
0.040.15
3 years
0.040.51
5 years
0.040.51
10 years
0.040.51
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Winlo
CEO | Chief Executive Officer | - | 19-10-02 |
Mary Ann Rennie
COO | Chief Operating Officer | - | - |
Tracie Ernenwein
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mohit Kaushal
BRD | Director/Board Member | 45 | 23-08-20 |
John Tooke
BRD | Director/Board Member | 75 | 18-03-22 |
Karen Smith
BRD | Director/Board Member | 56 | 21-11-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 0.052 | -1.89% | 480 410 |
| 24-07-02 | 0.053 | +15.22% | 994,603 |
| 24-07-01 | 0.046 | +12.20% | 133,877 |
| 24-06-28 | 0.041 | 0.00% | 587,834 |
| 24-06-27 | 0.041 | 0.00% | 461,324 |
Delayed Quote Australian S.E., July 03, 2024 at 01:36 am EDT
More quotes
Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 14.43M | |
| -35.02% | 13.14B | |
| +4.48% | 11.75B | |
| -6.31% | 11.22B | |
| +7.81% | 10.5B | |
| +28.25% | 8.62B | |
| -11.77% | 7.09B | |
| +12.23% | 7.11B | |
| +7.33% | 6.4B | |
| 0.00% | 4.24B |
- Stock Market
- Equities
- EMD Stock
